• 001NESOM Banner 1150x300

Overview

Provided by

i3 Health Logo

ACCREDITATION

This continuing nursing education activity was approved by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, AOCNP®, AOCNS®, and CBCN® renewal candidates: 1 ILNA point may be applied toward: 
Scientific Basis/Diagnosis or Survivorship or Professional ..............................1 point     

CPHON® renewal candidates: 1 ILNA point may be applied toward:
Survivorship or Professional or Disease Related Biology ................................1 point     

BMTCN® renewal candidates: 1 ILNA point may be applied toward: 
Survivorship or Professional or Post-Transplant Issues …................................1 point     

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.

STATEMENT OF NEED

Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Raber-Durlacher et al, 2010). Patients with OM may experience moderate to severe pain, sensation changes, difficulty talking and/or swallowing, xerostomia, and ulcers that bleed or are covered by a white pseudomembrane (Eilers & Million, 2011). Many patients cite OM as the most debilitating and disturbing side effect of their treatment.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

  • List the clinical consequences of mucositis in patients with cancer
  • Describe the pathogenesis of oral mucositis
  • Select appropriate scales for grading the severity of mucositis and instruments for measuring symptom distress
  • Describe the standards of care for oral mucositis as defined in the updated guidelines from the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology

REQUIREMENTS FOR CREDIT

To claim your CME/CE certificate for this activity, please complete the following steps:

  1. Read the monograph
  2. Pass the posttest with a score of ≥80%
  3. Complete the activity evaluation
  4. Download your certificate of completion

PREREQUISITES

No prerequisites are required for this activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CE activity to disclose all financial relationships with commercial interests that are related to the content of the CE activity. CE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

  • i3 Health staff members and the peer/content reviewer for this activity have no relevant financial relationships to disclose

UNAPPROVED USE DISCLOSURE

i3 Health requires CE faculty to disclose to participants when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty will not discuss information about pharmaceutical agents that is outside of FDA approved labeling. This information is intended solely for educational purposes and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

TECHNICAL/CREDIT QUERIES

Technical queries about this activity should be directed to This email address is being protected from spambots. You need JavaScript enabled to view it.

Start Activity